This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The primary objective is to assess the feasiblity of enrolling patients aged 70 or older with advanced urothelial cancer to a Ph II study. The efficacy, toxicity and tolerability will be assessed. self-reporting measures of comorbidity, depression and functional status will be evaluated. Clinical pharmacology of the drugs paclitaxel and gemcitabine in both this age group and those patients under 60 will be assessed. Those under 60 will be compared to patients reported in the literature. The feasibility of exploring genetic polymorphisms will be explored.
Showing the most recent 10 out of 565 publications